Spots Global Cancer Trial Database for Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients
Official Title: A Phase II Single-arm Trial of BIBW 2992 in Demographically and Genotypically Selected NSCLC
Study ID: NCT00730925
Conditions
Study Description
Brief Summary: The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by the RECIST criteria, in patients with advanced NSCLC Stage IIIB or IV whose tumours harbour activating mutations within exon 18 to exon 21 of the EGFR receptor, in patients with mutations in the HER2/neu receptor and in patients with EGFR FISH positive tumours with no EGFR mutations.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
1200.41.32003 Boehringer Ingelheim Investigational Site, Antwerpen, , Belgium
1200.41.32007 Boehringer Ingelheim Investigational Site, Charleroi, , Belgium
1200.41.32001 Boehringer Ingelheim Investigational Site, Jette, , Belgium
1200.41.32011 Boehringer Ingelheim Investigational Site, Leuven, , Belgium
1200.41.32008 Boehringer Ingelheim Investigational Site, Liège, , Belgium
1200.41.32006 Boehringer Ingelheim Investigational Site, Namur, , Belgium
1200.41.34001 Boehringer Ingelheim Investigational Site, Badalona (Barcelona), , Spain
Contact Details
Name: Boehringer Ingelheim
Affiliation: Boehringer Ingelheim
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
